PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

R. Migden, Michael; Rischin, Danny; D. Schmults, Chrysalyne; Guminski, Alexander; Hauschild, Axel; D. Lewis, Karl; H. Chung, Christine; F. Hernandez‐Aya, Leonel; M. Lim, Annette; Lynn S. Chang, Anne; Rabinowits, Guilherme; Thai, Alesha; Dunn, Lara; Hughes, Brett; I. Khushalani, Nikhil; Modi, Badri; Schadendorf, Dirk; Gao, Bo; Seebach, Frank; Li, Siyu; Li, Jingjin; Mathias, Melissa; Booth, Jocelyn; Kal Mohan, Kosalai; Stankevich, Elizabeth; M. Babiker, Hani; Braña, Irene; Gil-Martín, Marta; Homsi, Jade; L. Johnson, Melissa; Moreno, Víctor; Niu, Jiaxin; K. Owonikoko, Taofeek; P. Papadopoulos, Kyriakos; D. Yancopoulos, George; Lowy, Israel; G. Fury, Matthew

doi:10.1056/nejmoa1805131

Public

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Published in New England Journal of Medicine • Jun 4, 2018

Authors:

Michael R. Migden

Danny Rischin

Chrysalyne D. Schmults

Abstract

BACKGROUND: No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-esca...

Subject

Medicine

Cohort

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!